The SPAC and Life Sciences teams advised Pear Therapeutics in its business combination with Thimble Point Acquisition Corp. (Nasdaq: THMA), a special purpose acquisition company whose management team is associated with the Pritzker Vlock Family Office. The publicly traded company, Pear Therapeutics, Inc., will commence trading on Nasdaq under the ticker symbol “PEAR” on December 6, 2021. Thimble Point’s shareholders approved the business combination on November 30, 2021, and the transaction was previously approved by Pear Therapeutics’ shareholders.
The transaction generated approximately $175 million in gross cash proceeds for the combined company.
Pear Therapeutics, founded in 2013, is the leader in prescription digital therapeutics, or PDTs. Pear is redefining medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA.
The Goodwin team was led by Mike Patrone, Jocelyn Arel and Wei Xu, and included Loren Goodman, Crescent Moran Chasteen, James Devendorf, Janet Andolina, Kyle Pine, Jennifer Fay, Lee Douthitt, Roger Cohen, and Steven Tjoe.
For additional details on the transaction, please read the announcement press release, closing press release and coverage in The Wall Street Journal, Reuters, Boston Globe and STAT News.